Eli Lilly buys psychedelic drugmaker AtaiBeckley
Money MovesA $2.8 billion cash deal puts Lilly into a race with Johnson & Johnson for the next depression drugs
July 16th, 2026: Lilly agrees to buy AtaiBeckleyNew here? Follow stories to track developments over time. Create a free account to get updates when stories you care about change.
Overview
Updated Jul 16Eli Lilly agreed to buy AtaiBeckley for $6.75 a share in cash, about $2.8 billion, with up to $1 billion more if two drugs hit development targets. The purchase pulls one of the world's largest drugmakers into psychedelic medicine.
AtaiBeckley's lead drug is a nasal spray built on 5-MeO-DMT, a fast-acting psychedelic, aimed at people whose depression has not responded to standard pills. Lilly is betting that a single supervised dose can do what daily antidepressants often cannot.
Why it matters
Roughly a third of people with depression don't get better on standard drugs. Lilly is spending billions to change that with a psychedelic given once, under supervision.
Questions about this story
Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.
No questions yet — be the first to ask.
Key Indicators
Voices
Curated perspectives — historical figures and your fellow readers.
Play
Exploring all sides of a story is often best achieved with Play.
Higher or Lower
A number from this story, against one from elsewhere in the news — guess which is bigger, then keep the chain going. 5 rounds, 3 strikes; a miss costs a strike and resets your streak.
Keyboard: ↓/L lower · ↑/H higher
0 points — sign up to put that on the leaderboard.
Timeline
Order five events from this story, oldest at top. Each in the right slot scores 1 — neighbours within one slot count too. Your previous result — green ✓ for exact slots, yellow ~ for off by one. Cards now in true chronological order.
Sign up to save your score and track a streak across stories.
Connections
Sixteen names from the news. Find the four hidden groups of four. Four mistakes max.
Sign up to keep a daily streak — a new puzzle lands every day.
Exit debate?
Your progress in this debate will be lost.
- 1 Two AI personas square off on this story.
- 2 You predict who'll win each round — correct picks earn XP.
- 3 One crossfire question is yours to fire. Pick it carefully.
Couldn't generate a topic
Select Your Champions
Choose one persona for each side of the debate
DEBATE TOPIC
Choose personas with different perspectives for a more dynamic debate.
Select debater for this side:
No debate personas available right now.
Select debater for this side:
No debate personas available right now.
Who's Got This Round?
Make your prediction before the referee scores
The referee scores both sides on
Round Results
Set the Crossfire
Pick the question both personas must answer in the final round
Debate Oracle! You called every round!
Sharp Instincts! You know your debaters!
The Coin Flip Strategist! Perfectly balanced!
The Contrarian! Bold predictions!
Inverse Genius! Try betting the opposite next time!
XP Breakdown
Prediction History
People Involved
Organizations Involved
One of the world's largest drugmakers, based in Indianapolis, now buying its way into psychedelic mental-health treatment.
A psychedelic-focused drug developer formed from the 2025 merger of atai Life Sciences and Beckley Psytech.
Maker of Spravato, the ketamine-derived nasal spray that opened the market Lilly now wants to enter.
Timeline
June 2025 July 2026
-
Lilly agrees to buy AtaiBeckley
Latest DealEli Lilly announced a $6.75-per-share cash deal, about $2.8 billion, with up to $1 billion more tied to drug milestones. Closing is expected in the third quarter.
-
Lead drug advances toward Phase 3
ClinicalAtaiBeckley moved BPL-003 into its final trial stage after a successful end-of-Phase-2 meeting with the FDA.
-
AtaiBeckley is born
Corporateatai Life Sciences and Beckley Psytech completed their all-stock merger, forming AtaiBeckley with a runway into 2029.
-
FDA grants Breakthrough Therapy status
RegulatoryThe FDA named BPL-003 a Breakthrough Therapy for treatment-resistant depression, a status meant to speed its review.
-
Phase 2b data triggers merger
ClinicalBeckley Psytech's 5-MeO-DMT nasal spray cut depression scores in a 193-patient trial, prompting atai to move ahead with a merger.
Historical Context
2 moments from history that rhyme with this story — and how they unfolded.
Lilly's Prozac era (1987)
Lilly launched Prozac, the first blockbuster in a new class of antidepressants known as SSRIs. It made depression treatment mainstream and became one of the most prescribed drugs in the world.
Prozac reshaped psychiatry and generated billions in sales for Lilly through the 1990s.
Patents expired and big drugmakers, Lilly included, largely retreated from risky brain-drug research for years.
The AtaiBeckley deal marks Lilly returning to the depression market it once dominated, now through a psychedelic instead of a daily pill.
J&J's Spravato approval (2019)
The FDA approved Johnson & Johnson's Spravato, a nasal spray derived from the anesthetic ketamine, for treatment-resistant depression. It was the first genuinely new type of depression drug in decades and required patients to be dosed and monitored in certified clinics.
Uptake was slow at first as clinics and insurers adjusted to the supervised-dosing model.
Certified sites grew from about 2,800 in 2024 to over 7,000 by 2026, and quarterly sales topped $580 million.
Spravato proved the business model AtaiBeckley's drug would copy, and it is the exact product Lilly now wants to compete against.
